Recent Updates
Recently added Catalysts
IVF Positive Sentiment

INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

Key Takeaway: INVO Fertility, Inc. will participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The company will host a webcast presentation and one-on-one meetings with investors. INVO Fertility focuses on expanding access to assisted reproductive technology through its INVO Centers and proprietary INVOcell device, which enhances the IVF process.
Price reaction · baseline $198 (2025-05-27 close) · hit after-hours · clean, no other IVF news in the window
day 0 close · peak
+4.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • INVO Fertility is expanding access to advanced fertility treatments.
  • The company is actively engaging with investors through a virtual conference.
  • INVOcell technology offers a more natural and affordable ART experience.

Full Press Release Details

SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, will participate in a webcast fireside chat and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
Company Webcast
The webcast presentation will take place at 4:15 p.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/AlmOGnMNXag . The webcast will also be available for replay following the event.
1×1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1×1@lythampartners.com or register for the event at https://lythampartners.com/spring2025invreg/ .
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell ® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of our INVOcell technology solution into third-party owned and operated fertility clinics. The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. The IVC procedure provides patients with a more natural, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination (“IUI”). For more information, please visit www.invofertility.com .
For more information, please contact:

Frequently Asked Questions

When is the Lytham Partners Spring 2025 Investor Conference?

The conference will take place on May 29, 2025.

How can I access the INVO Fertility webcast?

The webcast can be accessed via the conference homepage or directly through a provided link.

What is the focus of INVO Fertility?

INVO Fertility focuses on expanding access to assisted reproductive technology and operates fertility clinics.

What technology does INVO Fertility use?

INVO Fertility uses the INVOcell device for its intravaginal culture procedure.

Last updated: May 27, 2025